@article {N{\'E}METH663, author = {BAL{\'A}ZS N{\'E}METH and ISTV{\'A}N KISS and IV{\'A}N P{\'E}TER and Z{\'E}N{\'O} AJTAY and {\'A}D{\'A}M N{\'E}METH and L{\'A}SZL{\'O} M{\'A}RK and ATTILA CSORBA and TAM{\'A}S K{\H O}SZEGI and DI{\'A}NA M{\"U}HL and P{\'E}TER KUST{\'A}N}, title = {Monitoring of L-Arginine and Endogenous Dimethylarginines in Survivor Septic Patients {\textendash} A Pilot Study}, volume = {30}, number = {5}, pages = {663--669}, year = {2016}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Nitric oxide (NO) pathway plays a major role in the development and advancement of inflammation. We aimed to design a study and investigate its feasibility to show the changes of L-arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), which are important regulators of the NO pathway. Patients and Methods: Concentrations of L-arginine, ADMA and SDMA were measured by liquid chromatography-tandem mass spectrometry. Seventeen septic survival patients were enrolled and blood samples were obtained on the first, third and fifth day after the diagnosis of sepsis. Sixteen non-septic matched controls were recruited. Results: ADMA levels on admission correlated well with sequential organ failure assessment (SOFA) score. During the follow-up, L-arginine/ADMA ratio increased significantly from day 1 to day 3 (p=0.005), then decreased from day 3 to day 5 (p=0.023). Conclusion: This study design seems feasible to investigate changes of L-Arginine, ADMA and SDMA in sepsis survival patients.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/30/5/663}, eprint = {https://iv.iiarjournals.org/content/30/5/663.full.pdf}, journal = {In Vivo} }